Home » Caliper Cuts '06 Outlook as SEC Review Delays Xenogen Acquisition

Caliper Cuts '06 Outlook as SEC Review Delays Xenogen Acquisition

Jul 13, 2006
NEW YORK (GenomeWeb News) - Caliper Life Sciences lowered its previously announced financial outlook for the year due to an SEC review of the company's plan to buy Xenogen, which delayed the acquisition, the company said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.